- Home
- EDD vs TSHA Comparison
EDD vs TSHA Comparison
Compare EDD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- TSHA
- Stock Information
- Founded
- EDD 2007
- TSHA 2019
- Country
- EDD United States
- TSHA United States
- Employees
- EDD N/A
- TSHA N/A
- Industry
- EDD Finance Companies
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- TSHA Health Care
- Exchange
- EDD Nasdaq
- TSHA Nasdaq
- Market Cap
- EDD 307.8M
- TSHA 334.1M
- IPO Year
- EDD N/A
- TSHA 2020
- Fundamental
- Price
- EDD $4.82
- TSHA $1.61
- Analyst Decision
- EDD
- TSHA Strong Buy
- Analyst Count
- EDD 0
- TSHA 8
- Target Price
- EDD N/A
- TSHA $6.63
- AVG Volume (30 Days)
- EDD 254.3K
- TSHA 2.1M
- Earning Date
- EDD 01-01-0001
- TSHA 02-26-2025
- Dividend Yield
- EDD 7.52%
- TSHA N/A
- EPS Growth
- EDD N/A
- TSHA N/A
- EPS
- EDD N/A
- TSHA N/A
- Revenue
- EDD N/A
- TSHA $9,915,000.00
- Revenue This Year
- EDD N/A
- TSHA N/A
- Revenue Next Year
- EDD N/A
- TSHA N/A
- P/E Ratio
- EDD N/A
- TSHA N/A
- Revenue Growth
- EDD N/A
- TSHA N/A
- 52 Week Low
- EDD $4.22
- TSHA $1.19
- 52 Week High
- EDD $4.95
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EDD 65.82
- TSHA 46.14
- Support Level
- EDD $4.68
- TSHA $1.46
- Resistance Level
- EDD $4.82
- TSHA $1.76
- Average True Range (ATR)
- EDD 0.06
- TSHA 0.15
- MACD
- EDD 0.00
- TSHA 0.01
- Stochastic Oscillator
- EDD 95.17
- TSHA 39.33
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.